ASND (Ascendis Pharma AS) Earnings per share for the last four quarters

Ascendis Pharma Inc. (ASND) - corporate logo

Ascendis Pharma A/S (ASND) monetizes an innovative delivery system for endocrine agents used in the therapy of rare pathologies. The measurement of annual EPS TTM growth demonstrates market dynamics where 485.80 represents the latest level. High cold chain compliance costs during transport are offset by growing clinic demand for unique drugs, which expands the customer base and strengthens physician loyalty.

ASND ascendispharma.com Net earnings per share (EPS TTM) (02/11/2024 - 11/15/2026)

ASND (Ascendis Pharma A/S): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Ascendis Pharma Inc.|ASND - Consensus Target
- business market valuation indicators:
Market Value Ascendis Pharma Inc.|ASND - Enterprise Value
- business book valuation details:
Book Value per Share Ascendis Pharma|ASND - Book Capitalization|Market Value to Book Value Ratio ascendispharma.com|ASND - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Capital Ascendis Pharma A/S|ASND - Long-Term Debt to Equity|Short-Term Debt to Equity Ascendis Pharma A/S|ASND - Company Aggregate Debts|Debts to Net Assets Ascendis|ASND - Company Long-Term Debt|Short-Term Debt Volume Ascendis Pharma|Quick Liquidity Indicator ascendispharma.com
- earnings and multiples data:
ASND - Net Profit|Projected Future Earnings Ascendis Pharma A/S|ASND - Price to Earnings Ratio|Market Cap to Projected Earnings Ascendis Pharma Inc.|ASND - PEG Multiple|Enterprise Value to EBITDA Ratio Ascendis Pharma Inc.|ASND - Operating profit EBITDA|Net earnings per one share for the last twelve months Ascendis Pharma|ASND - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months ascendispharma.com|ASND - Earnings growth in current year|Projected earnings per share growth rate for next year Ascendis Pharma A/S
- sales and revenue indicators:
ASND - Revenue and Sales Volume|Company Future Sales Ascendis Pharma AS|ASND - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Ascendis Pharma
Fundamental company valuation:ASND (Ascendis Pharma AS)
Core merchandise of Ascendis

This indicator measures the dynamics of rolling net income per share, reflecting the speed of business capitalization through the continuous discounting of future earnings. Analyzing growth rates helps avoid purchasing an asset at the peak of its momentum, thereby minimizing the risk of long-term drawdowns. The annual growth of basic net income per share (TTM) visualizes the efficiency of innovation monetization. For Ascendis Pharma A/S (ASND), this confirms the commercial success of its patented extended-release technology for endocrine drugs.

Competitor analysis

Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS